Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients

Tohoku Journal of Experimental Medicine

Volumn 228, Issue 2, 2012, Pages 85-92

  Sato, Douglas Kazutoshi ^a   Nakashima, Ichiro ^a   Fukazawa, Toshiyuki ^b   Shimizu, Yuko ^c   Tomizawa, Yuji ^d   Yokoyama, Kazumasa ^d   Misu, Tatsuro ^a   Creeke, Paul I ^e   Farrell, Rachel ^f   Giovannoni, Gavin ^e   Itoyama, Yasuto ^g   Fujihara, Kazuo ^a   Aoki, Masashi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sapporo Neurology Clinic   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Beta interferon; Immunomodulatory therapy; Multiple sclerosis; Neutralizing antibodies; Serologic tests

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CAUCASIAN; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOASSAY; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; RELAPSE; REPORTER GENE; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT DURATION;

ANTIBODIES, NEUTRALIZING; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; INTERFERON-BETA; LUCIFERASES; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 84867873777     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.228.85     Document Type: Article

References (22)

1. Buck, D., Cepok, S., Hoffmann, S., Grummel, V., Jochim, A., Berthele, A., Hartung, H.P., Wassmuth, R. & Hemmer, B. (2011) Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch. Neurol., 68, 480-487.
2. Ebers, G.C., Traboulsee, A., Li, D., Langdon, D., Reder, A.T., Goodin, D.S., Bogumil, T., Beckmann, K., Wolf, C. & Konieczny, A. (2010) Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiatry, 81, 907-912.
3. Farrell, R., Kapoor, R., Leary, S., Rudge, P., Thompson, A.J., Miller, D.H. & Giovannoni, G. (2008) Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult. Scler., 14, 212-218.
4. Farrell, R.A., Marta, M., Gaeguta, A.J., Souslova, V., Giovannoni, G. & Creeke, P.I. (2012) Development of resistance to biologic therapies with reference to IFN-beta. Rheumatology, 51, 590-599.
5. Giovannoni, G., Munschauer, F.E. 3rd. & Deisenhammer, F. (2002) Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 73, 465-469.
6. Grossberg, S.E., Kawade, Y., Kohase, M., Yokoyama, H. & Finter, N. (2001a) The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res., 21, 729-742.
7. Grossberg, S.E., Kawade, Y., Kohase, M. & Klein, J.P. (2001b) The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res., 21, 743-755.
8. Hartung, H.P., Freedman, M.S., Polman, C.H., Edan, G., Kappos, L., Miller, D.H., Montalban, X., Barkhof, F., Petkau, J., White, R., Sahajpal, V., Knappertz, V., Beckmann, K., Lanius, V., Sandbrink, R. & Pohl, C. (2011) Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, 77, 835-843.
9. Hoffmann, S., Cepok, S., Grummel, V., Lehmann-Horn, K., Hackermuller, J., Stadler, P.F., Hartung, H.P., Berthele, A., Deisenhammer, F., Wassmuth, R. & Hemmer, B. (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferonbeta therapy in multiple sclerosis. Am. J. Hum. Genet., 83, 219-227.
10. Isobe, N., Matsushita, T., Yamasaki, R., Ramagopalan, S.V., Kawano, Y., Nishimura, Y., Ebers, G.C. & Kira, J. (2010) Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult. Scler., 16, 147-155.
11. Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J., Simonian, N.A., Slasor, P.J. & Sandrock, A.W. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med., 343, 898-904.
12. Lam, R., Farrell, R., Aziz, T., Gibbs, E., Giovannoni, G., Grossberg, S. & Oger, J. (2008) Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients. J. Immunol. Methods, 336, 113-118.
13. Lassmann, H. (2010) What drives disease in multiple sclerosis: Inflammation or neurodegeneration? Clin. Exp. Neuroimmunol., 1, 2-11.
14. Lundkvist, M., Greiner, E., Hillert, J. & Fogdell-Hahn, A. (2010) Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Mult. Scler., 16, 796-800.
15. McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D., McFarland, H.F., Paty, D.W., Polman, C.H., Reingold, S.C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., Van Den Noort, S., Weinshenker, B.Y. & Wolinsky, J.S. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol., 50, 121-127.
16. McElroy, J.P., Isobe, N., Gourraud, P.A., Caillier, S.J., Matsushita, T., Kohriyama, T., Miyamoto, K., Nakatsuji, Y., Miki, T., Hauser, S.L., Oksenberg, J.R. & Kira, J. (2011) SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun., 12, 523-530.
17. Pachner, A.R., Warth, J.D., Pace, A. & Goelz, S. (2009) Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology, 73, 1493-1500.
18. Paty, D.W. & Li, D.K. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 43, 662-667.
19. Polman, C.H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H.P., Hemmer, B., Killestein, J., McFarland, H.F., Oger, J. & Pachner, A.R. (2010) Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol., 9, 740-750.
20. Saida, T., Tashiro, K., Itoyama, Y., Sato, T., Ohashi, Y. & Zhao, Z. (2005) Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology, 64, 621-630.
21. Sorensen, P.S. (2008) Neutralizing antibodies against interferon-Beta. Ther. Adv. Neurol. Disord., 1, 62-78.
22. Sorensen, P.S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K.M., Palace, J., Polman, C., Pozzilli, C. & Ross, C. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur. J. Neurol., 12, 817-827.